355 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Peterson Financial Group Inc.

Peterson Financial Group Inc. bought a new position in Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 355 shares of the medical research company’s stock, valued at approximately $114,000.

Other hedge funds have also modified their holdings of the company. Meyer Handelman Co. grew its holdings in shares of Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after acquiring an additional 8,700 shares during the last quarter. EP Wealth Advisors LLC grew its holdings in shares of Amgen by 11.0% in the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock worth $6,758,000 after acquiring an additional 2,353 shares during the last quarter. Cornerstone Capital Inc. grew its holdings in shares of Amgen by 3.2% in the 3rd quarter. Cornerstone Capital Inc. now owns 106,538 shares of the medical research company’s stock worth $34,328,000 after acquiring an additional 3,260 shares during the last quarter. Stanley Laman Group Ltd. purchased a new position in shares of Amgen during the second quarter valued at $3,354,000. Finally, Verity & Verity LLC grew its holdings in shares of Amgen by 2.7% during the second quarter. Verity & Verity LLC now owns 82,368 shares of the medical research company’s stock valued at $25,736,000 after buying an additional 2,182 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 4.2 %

Shares of NASDAQ:AMGN opened at $283.61 on Friday. The company has a 50-day simple moving average of $320.85 and a 200 day simple moving average of $318.36. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market capitalization of $152.45 billion, a P/E ratio of 36.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60. Amgen Inc. has a 52-week low of $260.52 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the business posted $4.96 earnings per share. Sell-side analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.17%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AMGN shares. Robert W. Baird reiterated an “underperform” rating and set a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. Bank of America lifted their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Barclays lifted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and lifted their price target for the company from $320.00 to $333.00 in a report on Monday, October 14th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.